Published on 29 May 2024 on Zacks via Yahoo Finance
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
Shares of Insmed INSM more than doubled in market value on Tuesday after reporting positive topline results from the phase III ASPEN study which evaluated its investigational oral drug brensocatib in patients with bronchiectasis.
The ASPEN study evaluated two different doses of brensocatib — 10mg and 25mg — against placebo in patients with non-cystic fibrosis bronchiectasis. The study met its primary endpoint — both doses of the drug achieved statistically significant and clinically meaningful reductions in the annualized rate of pulmonary exacerbations (or episodes of worsening disease symptoms) when compared with placebo.